PureIMS
Private Company
Funding information not available
Overview
PureIMS is a private, clinical-stage biotech leveraging its proprietary Cyclops® dry powder inhaler platform to develop inhaled therapies for respiratory and systemic conditions. Its lead program, Colistin Cyclops®, is already marketed under a named patient regimen in the Netherlands for cystic fibrosis, with over 100,000 doses prescribed, demonstrating early commercial traction. The company has a pipeline including programs for Parkinson's disease and anaphylaxis, and it actively pursues co-development partnerships, supported by a seasoned management team and non-dilutive grant funding.
Technology Platform
Proprietary Cyclops® pre-filled, passive dry powder inhaler (DPI) designed for cost-effective manufacturing, ease of use, portability, and hygiene. It uses the patient's breath to disperse powder for deep lung deposition.
Opportunities
Risk Factors
Competitive Landscape
PureIMS competes in the DPI space against large device manufacturers (e.g., AstraZeneca, GSK, Novartis) and specialized drug-device companies. For Levodopa Cyclops®, the direct competitor is Acorda's Inbrija®. For Epinephrine, it competes against auto-injector giants like Viatris (EpiPen). Its differentiation lies in the pre-filled, cost-effective, and patient-centric design of the Cyclops® device.